• Enanta Pharmaceuticals Inc ENTA.OQ reported a quarterly adjusted loss of $1.05​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.58. The mean expectation of five analysts for the quarter was for a loss of $1.35 per share. Wall Street expected results to range from $-1.50 to $-1.16 per share.

• Revenue fell 5.8% to $16.96 million from a year ago; analysts expected $17.25 million.

• Enanta Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.05​.

• The company reported a quarterly loss of $22.29 million.

• Enanta Pharmaceuticals Inc shares had fallen by 14.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 15.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $19.00

This summary was machine generated from LSEG data February 10 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)